Supporting IND Application and Regulatory Operations in China for a Cell and Gene Therapy (CGT) Product

Delivering comprehensive China Regulatory Affairs support, IND application management, Regulatory operations, and NMPA consulting services for an innovative Cell and Gene Therapy (CGT) product while ensuring compliance with China's evolving Regulatory framework and accelerating the pathway toward clinical development and market access.

Timely

response to NMPA queries, submitted 4 days ahead of the deadline

Strategic

support for conditional approval and priority review pathways

End-to-end

Regulatory operations and CMC consulting support

Client Overview
Icon

Client Overview

A China-based biopharmaceutical company developing an innovative Cell and Gene Therapy (CGT) product required comprehensive Regulatory Affairs and Regulatory Operations support for its Investigational New Drug (IND) application in China. The client sought expert guidance to navigate NMPA Regulatory pathways, IND submission requirements, CMC documentation, Regulatory consultation processes, and clinical development planning for an advanced therapy product.

Background Icon

Background

As part of its clinical development and commercialization strategy, the client planned to submit an IND application to China's National Medical Products Administration (NMPA) for an innovative CGT therapy. Given the novel nature of Cell and Gene Therapy products, the Regulatory pathway involved complex technical evaluations, evolving guidance, and heightened scrutiny of Chemistry, Manufacturing, and Controls (CMC) documentation.

The organization required an experienced Regulatory partner capable of managing Regulatory operations, supporting NMPA consultations, addressing technical queries, and developing strategies for accelerated approval pathways to ensure submission success and timely clinical trial initiation.

Scope Icon

Services in Scope

IND Application Support and Regulatory Operations Management

NMPA Consultation and Regulatory Communication

CMC Change Assessment and Regulatory Strategy

Clinical Trial Documentation Management

IND Dossier Preparation and Review

DSUR and End-of-Phase Interaction (EoPI) Support

NMPA Query Response Management

Conditional Approval and Priority Review Planning

Challenge
Challenge

Challenge

Challenge

Evolving NMPA Requirements for CGT Products The client faced challenges in interpreting and aligning documentation with China's evolving Regulatory expectations for Cell and Gene Therapy products. 

Challenge

Limited Regulatory Precedent The innovative CGT platform leveraged advanced technology with limited Regulatory precedent and evolving guidance within the Chinese Regulatory landscape. 

Challenge

Complex CMC-Related Queries Responding effectively to highly technical CMC-related questions from the NMPA was critical to maintaining submission momentum and avoiding delays. 

Challenge

Regulatory Strategy for Accelerated Pathways The client required guidance on conditional approval and priority review pathways to support faster clinical development and potential market access. 

Challenge

Solution

1
Challenge
End-to-End IND Application Support

Provided comprehensive support for IND application execution, Regulatory documentation review, submission planning, and Regulatory consultation activities.

2
Challenge
Proactive NMPA Query Management

Developed and coordinated responses to NMPA questions, delivering responses four days ahead of the deadline to support smooth IND approval.

3
Challenge
CMC Regulatory Consulting

Provided strategic consultation on major CMC changes, technical documentation requirements, and Regulatory expectations for advanced therapies.

4
Challenge
Clinical Trial Documentation Support

Managed critical clinical development documentation, including IND dossiers, Development Safety Update Reports (DSURs), and End-of-Phase Interactions (EoPI).

5
Challenge
Accelerated Approval Strategy

Supported planning for conditional approval and priority review pathways, helping position the product for expedited Regulatory review and faster patient access.

Challenge

Impact

Freyr's support enabled the client to successfully navigate the complex Regulatory landscape for Cell and Gene Therapy products in China while strengthening submission quality, compliance, and Regulatory readiness.

Challenge
Regulatory Excellence 
  • Ensured alignment with China NMPA requirements
  • Supported successful IND approval activities
  • Delivered high-quality Regulatory communication materials
  • Strengthened compliance with evolving CGT Regulatory expectations 
Challenge
Faster Submission Execution 
  • Submitted NMPA query responses ahead of deadlines
  • Accelerated Regulatory consultation and approval activities
  • Reduced the risk of submission delays and review interruptions 
Challenge
Operational Efficiency 
  • Streamlined Regulatory operations and documentation management
  • Improved coordination between stakeholders and Regulatory authorities
  • Enhanced visibility into submission progress and Regulatory milestones 
Challenge
Business Value 
  • Supported successful progression into clinical development
  • Improved readiness for conditional approval and priority review opportunities
  • Strengthened the client's China market access strategy
  • Enabled faster advancement of an innovative Cell and Gene Therapy program